Establishment of Ovarian Cancer Cell Lines
Human tumor cell lines have provided valuable model systems to study a wide variety of tumor characteristics including the cell biology, genetics, and chemosensitivity profiles of disease. A large number of ovarian cancer cell lines have now been established and are in widespread use Table 1 ) (1 -15 ). Many of these have been selected to reflect specific situations, e.g., pre- and postchemotherapy models or different histo- logical subtypes. Table 1 Properties of Established Ovarian Carcinoma Cell Lines
Prior | ||||
|---|---|---|---|---|
Cell Line | Histology | Source | Treatment | Ref. |
PE01 | P.D. Serous adenoca | Ascites | P/FU/CHL | 1 |
PE04 | P.D. Serous adenoca | Ascites | P/FU/CHL | 1 |
PE06 | P.D. Serous adenoca | Ascites | P/FU/CHL | 2 |
PEA1 | P.D. Adenoca | Pleural | None | 2 |
PEA2 | P.D. Adenoca | Ascites | P/Pred | 2 |
PE016 | P.D. Serous adenoca | Ascites | Radioth | 2 |
PE014 | W.D.Serous adenoca | Ascites | None | 2 |
T014 | W.D.Serous adenoca | Sol. Met | None | 2 |
PE023 | W.D.Serous adenoca | Ascites | P/CHL | 2 |
SKOV-3 | Adenoca | Ascites | T | 3 |
SW626 | Adenoca | ― | ― | 3 |
OVCAR-2 | Adenoca | Ascites | P/Cy | 4 |
OVCAR-3 | P.D. papillary adenoca | Ascites | P/Cy/Adr | 5 |
OVCAR-4 | Adenoca | Ascites | P/Cy/Adr | 6 |
OVCAR-5 | Adenoca | Ascites | None | 7 |
OAW 28 | Adenoca | Ascites | P / Mel | 8 |
OAW 42 | Serous adenoca | Ascites | P | 8 |
41M | Adenoca | Ascites | None | 9 |
59M | Endometr adenoca | Ascites | None | 8 |
CH1 | Papillary adenoca | Ascites | P/ JM8 | 8 |
138D | Serous adenoca | Ascites | Carb | 9 |
180D | Adenoca | Ascites | P | 9 |
200D | Serous adenoca | Solid | None | 9 |
253D | Serous adenoca | Ascites | Cy/MPA | 9 |
HOC-1 | W.D. Serous adenoca | Ascites | None | 10 |
HOC-7 | W.D. Serous adenoca | Ascites | None | 10 |
CAOV-3 | Adenoca | Tumour | Cy/Adr/FU | 10 |
COLO 110 | Serous adenoca | Sol. Met | None | 11 |
COLO 316 | Serous adenoca | Pleural | None | 11 |
COLO 319 | Serous adenoca | Ascites | None | 11 |
COLO 330 | Serous adenoca | Ascites | Mel/Radiother | 11 |
IGROV1 | Adenoca | Primary | None | 12 |
HTOA | W.D. serous adenoca | Primary | None | 13 |
OV-1063 | Papillary adenoca | Ascites | Cy/Adr/P/HMM | 14 |
DO-s | W.D. mucinous adenoca | Ascites | ― | 15 |
P.D. = Poorly differentiated; W.D. = Well differentiated; adenoca = adenocarcinoma; pleural = pleural effusion; Sol.met. = solid metastasis; P = cisplatin; FU = 5-fluorouracil; CHL = chlorambucil; Pred = prednimustine; Radioth = radiotherapy; T = thiotepa; Cy = cyclophosphamide; Adr = adriamycin; Mel = melphalan; Carb = carboplatin; MPA = medroxyprogesterone actetate; HMM = examethylmelamine.
相关文章
